Arlington Financial Advisors LLC Acquires 3,476 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Arlington Financial Advisors LLC increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 25.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,967 shares of the medical equipment provider's stock after purchasing an additional 3,476 shares during the quarter. Intuitive Surgical makes up approximately 1.5% of Arlington Financial Advisors LLC's portfolio, making the stock its 22nd biggest holding. Arlington Financial Advisors LLC's holdings in Intuitive Surgical were worth $8,403,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its position in Intuitive Surgical by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 32,212,196 shares of the medical equipment provider's stock valued at $16,813,478,000 after buying an additional 360,591 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Intuitive Surgical by 3.2% during the fourth quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock valued at $4,039,200,000 after purchasing an additional 243,802 shares during the last quarter. Fisher Asset Management LLC raised its holdings in Intuitive Surgical by 1.8% in the 4th quarter. Fisher Asset Management LLC now owns 4,868,869 shares of the medical equipment provider's stock worth $2,541,356,000 after acquiring an additional 86,488 shares during the last quarter. Norges Bank purchased a new position in Intuitive Surgical in the 4th quarter worth approximately $2,401,493,000. Finally, Invesco Ltd. raised its holdings in Intuitive Surgical by 7.7% in the 4th quarter. Invesco Ltd. now owns 4,148,180 shares of the medical equipment provider's stock worth $2,165,184,000 after acquiring an additional 295,025 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ISRG. Truist Financial decreased their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Evercore ISI decreased their target price on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday, April 23rd. Erste Group Bank downgraded shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 17th. Robert W. Baird cut their price objective on shares of Intuitive Surgical from $600.00 to $575.00 and set an "outperform" rating for the company in a research report on Wednesday, April 23rd. Finally, Barclays lowered their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus price target of $596.05.

Intuitive Surgical Price Performance

NASDAQ ISRG traded down $1.44 during trading on Tuesday, reaching $551.85. 1,713,548 shares of the company's stock were exchanged, compared to its average volume of 1,647,416. Intuitive Surgical, Inc. has a fifty-two week low of $397.47 and a fifty-two week high of $616.00. The business has a 50 day moving average price of $517.32 and a 200-day moving average price of $538.73. The stock has a market capitalization of $197.79 billion, a P/E ratio of 86.09, a PEG ratio of 5.85 and a beta of 1.70.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a return on equity of 14.55% and a net margin of 27.81%. The firm had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. During the same period in the prior year, the company earned $1.50 earnings per share. On average, analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Mark Brosius sold 492 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $554.17, for a total value of $272,651.64. Following the completion of the sale, the senior vice president now directly owns 3,072 shares in the company, valued at $1,702,410.24. This trade represents a 13.80% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Brian Edward Miller sold 8,900 shares of Intuitive Surgical stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $485.07, for a total value of $4,317,123.00. Following the transaction, the executive vice president now owns 5,758 shares of the company's stock, valued at $2,793,033.06. This trade represents a 60.72% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,778 shares of company stock valued at $12,867,197 in the last three months. Insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.